Impairment in autophagy-lysosomal pathway (ALP) results in accumulation of misfolded proteins and dysfunctional organelles, which is the hallmark of neurodegenerative diseases including Parkinson's disease (PD). Recent studies revealed activated nonreceptor tyrosine kinase Abelson (c-Abl) in PD models and brain specimen of PD patients. Inhibition of c-Abl through pharmacological inhibitors has been shown to enhance ALP function and provide neuroprotective effects in cells and animal models of PD. However, the molecular mechanisms of neuroprotective effects underlying c-Abl inhibition remain elusive. In this study, STI-571, a c-Abl inhibitor, rescued the ALP function through facilitating the nuclear translocation of TFEB and protected against MPP þ -induced neuronal cell death. Furthermore, siRNA-mediated knock-down or pharmacological inhibition of GSK3b mitigated the MPP þ -induced neuronal cell death, which was achieved through promoting TFEB nuclear localization and subsequently reversing the function of ALP. Intriguingly, either DPH, c-Abl activator, or MPP þ led to the activation of GSK3b, which is a negative regulator of TFEB. In addition, c-Abl directly interacted with GSK3b and catalyzed its phosphorylation at tyrosine 216, and their interaction was enhanced under MPP þ treatment.
Parkinson's disease (PD) is the second most common neurodegenerative disorders whose clinical symptoms include bradykinesia, resting tremor, muscle rigidity, and flexed posture (Kalia and Lang, 2015) . During the past 30 years, dopamine replacement is the mainstay for PD therapy. However, those dopaminergic medications such as levodopa which is used to treat motor symptoms in PD, lose efficacy, and cause dyskinesias and behavioral abnormalities in many patients (Lang and Espay, 2018) . The development and validation of effective mechanism-based therapies require exploring the underlying mechanism of PD etiology. The presence of proteinaceous cytoplasmic inclusions (Lewy bodies) in nigral dopaminergic neurons, a capital hallmark of PD, suggests that defective protein degradation may contribute to the progression of PD pathogenesis . Although multiple protein degradation pathways are involved in protein homeostasis, autophagy-lysosomal pathway(ALP) can selectively remove long-lived proteins, protein aggregates, and damaged organelles, such as mitochondria (Chu et al., 2014) . 1-methyl-4-phenylpyridinium ion (MPP þ ), an active metabolite of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP), is selectively taken up by dopaminergic neurons and has been extensively used to establish in vitro experimental model of PD (Przedborski and Vila, 2003; Wang et al., 2011) . Although MPP þ has been shown to induce impairment of ALP, the underlying mechanisms are not yet identified.
Recent studies in PD animal models and the analyses of postmortem PD brain specimen indicated that the level and activity of nonreceptor tyrosine kinase c-Abl were elevated (Hebron et al., 2013; Mahul-Mellier et al., 2014) . Yuan and Cheng (Wu et al., 2016; Zhou et al., 2017) discovered that c-Abl mediated MPTP-induced neuronal cell death by phosphorylating p38a and Drp1. In addition, several independent reports found that c-Abl inhibited Parkin's E3 ubiquitin ligase activity via phosphorylation, leading to neurotoxic accumulation of Parkin's substrates (Imam et al., 2011; Ko et al., 2010) . Alphasynuclein had also been identified to be phosphorylated by cAbl at the tyrosine residue 39, which negatively regulated its clearance by ALP (Mahul-Mellier et al., 2014) . Moreover, Lawana et al. (2017) proposed that c-Abl was involved in rotenoneinduced NLRP3 inflammasome activation and ALP dysfunction in microglia through modulation of transcription factor EB (TFEB). However, the role of c-Abl on ALP dysfunction in PD and its molecular mechanism remain largely unknown.
Glycogen synthase kinase-3 b(GSK3b) is a key regulator of TFEB which coordinates autophagy induction and lysosomal formation Marchand et al., 2015) . In addition, several lines of evidence have revealed that GSK3b triggered phosphorylation of a-synuclein and tau and are involved in the pathogenesis of PD (Credle et al., 2015) . However, it is unclear whether inhibiting GSK3b has a neuroprotective effect on PD model through reversing ALP dysfunction. GSK3b can be activated by phosphorylation of the tyrosine 216 (Tyr216) located in the kinase domain whereas inactivated by phosphorylation of the N-terminal serine 9 residue (Ser9). Growing studies have demonstrated that the inactive form of GSK3b (p-GSK3b-Ser9) is decreased Wang et al., 2017) , whereas the active form of GSK3b (p-GSK3b-Tyr216) is elevated in PD models and in postmortem PD patient tissues (Wills et al., 2010) . Many protein kinases are capable of phosphorylating GSK3b at Ser9, including Akt/PKB, protein kinase A (PKA), and protein kinase C (PKC) (Ku et al., 2011; Moore et al., 2013) . On the other hand, Pyk-2, Fyn, and MEK1/2 have been reported to phosphorylate GSK3b on Tyr216 (Gao et al., 2015; Takahashi-Yanaga et al., 2004) . Furthermore, an alternative hypothesis has been proposed that GSK3b can autoactivate itself by intramolecular autophosphorylation of Tyr216, and Hsp90 chaperone activity is required for this event (Lochhead et al., 2006) . While the actual mechanism of GSK3b-Tyr216 phosphorylation in PD needs further investigation.
In this study, we demonstrate that c-Abl is involved in MPP þ -induced impairment of the ALP and GSK3b is a direct substrate of c-Abl. Inhibition of c-Abl not only reduces the phosphorylation of GSK3b at Tyr216, but also rescues the ALP dysfunction via activating TFEB and protects against neuronal cell death in MPP þ -induced PD model. These findings suggest that c-Abl-GSK3b signaling pathway may be a potential therapeutic target for PD.
MATERIALS AND METHODS

Reagents. MPP
þ was obtained from Sigma-Aldrich (Munich, Germany). c-Abl inhibitor STI571 (Imatinib mesylate) and GSK3b inhibitor CHIR-99021 were purchased from Selleck Chemicals (Houston). c-Abl activator DPH was from MedChem Express (Monmouth Junction, New Jersey). Cell cytoplasmic and nuclear protein extraction kit was from Keygen Biotech (KGP1100, KeyGEN, NanJing, China). The following antibodies were used: anti-LC3A/B, anti-GSK3b, anti-phospho-GSK3a/bSer9/21, anti-cAbl, anti-14-3-3 antibodies (Cell Signaling Technologies, Danvers, Massachusetts); anti-Lamp-1, anti-p62, anti-Tubulin, anti-GFP, anti-TFEB, anti-LaminA/C antibodies (Proteintech, Rosemont, Illinois); anti-TFEB antibody (Abcam, Cambridge, UK); anti-phospho-c-AblTyr245, anti-phosphor-GSK3bTyr216 antibodies (Affinity biosciences, Cell Signal Transduction).
SN4741 cell culture and transfection. SN4741 cells were maintained in Dubbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, New York), 1% glucose, 100 U/ml penicillin-streptomycin, L-glutamine, and at 33 C in a humidified incubator with 5% CO 2 . Cell were transfected with RNA oligonucleotides and expression plasmids using Lipofectamine 3000 regent (Invitrogen, Carlsbad, California) Rat primary midbrain neuron culture. Dissociation of midbrain neurons from Sprague Dawley rat embryos was done as described previously (Gaven et al., 2014) . Midbrain neurons were maintained in DMEM/F12 supplemented with 10% FBS, 1% L-glutamine and 100 U/ml penicillin-streptomycin at 37 C with 5% CO 2 . After 24 h, medium was replaced by B-27 Plus Neuronal Culture System (Thermo Fisher, A3656401) and incubated at 37 C with 5% CO 2 . Medium was half-changed for every 3 days.
On day 7, cells were used for experiments.
Cell viability assays. Cell viability was measured using a Cell Counting Kit-8 (CCK-8) assay (Dojindo, Japan). About10 uM of WST-8 reagent was added to medium and SN4741 cells were incubated for 2 h at 33 C with 5% CO 2 . The absorbance of the sample was measured using a microplate reader at 450 nm.
Reverse transcription and semi-quantitative PCR. Total RNA was extracted from SN4741 cells using TRIzol reagent (Takara, Japan). Reverse transcription was performed, and followed by semi-quantitative PCR using the PrimeScript V R RT-PCR Kit (Takara, Japan). PCR primers were: Lamp-1, F 5 0 -CCTACGAGAC
The reaction conditions were according to the manufacturer's recommendations. PCR products were separated on a 2% agarose gel, stained with ethidium bromide, scanned with the Gel Doc XRþSysterm (BIO-RAD). Immunoblotting and co-immunoprecipitation. Cell were lysed in icecold lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl and 1% Triton X-100) supplemented with protease inhibitor cocktail (Roche, St, Louis, Missouri) and phosphatase inhibitor cocktail (Roche) for 10 min at 4 C. Cytosolic and nuclear fractions were collected using a nuclear exaction kit (KGP1100, KeyGen, Nanjing, China). Equal amount of total proteins (50 lg) determined by Bradford method (BioRad, Marnes-La-Coquette, France) were separated on 10% or 15% SDS-PAGE then transferred onto PVDF membranes (Millipore, Billerica, Machaassuchets). Blots were incubated in 5% BSA for 1 h at room temperature and subsequently probed with primary antibodies overnight at 4 C. After incubating for 1 h with IRDye 700/800 Secondary antibodies, protein level was scanned by Li-COR Odyssey infrared imaging system and analyzed by ImageJ software. The purity of subcellular fractionation were measured, as shown in Supplemental Fig.1 . For immunoprecipitation, cells were lysed as described above and protein lysates were incubated with corresponding antibody overnight at 4 C. Next day, 100 ul agarose beads were added to the sample and rotated for 2 h at 4 C. After washing three times, the immunoprecipitates were boiled with 2ÂSDS-PAGE sample buffer for immunoblotting.
Statistical analysis. All experiments were repeated at least three times. All values were described as mean 6 SEM. Comparisons between 2 groups were performed with 2-tailed unpaired Student's t-tests, and those between more than 2 groups were performed with 1-way ANOVA with Tukey's post-test of multiple comparisons. A P-value less than .05 was considered statistically significant.
RESULTS
Effects of MPP 1 on Autophagy and Lysosomal Biogenesis in SN4741 Cells
To test the optimal concentration of MPP þ on MPP þ -induced injury of SN4741 cells, the viability of SN4741 cells was measured using CCK-8 assay Kit. The results showed that the viability of cells decreased remarkably after treatment with 200 lM MPP þ for 24 h ( Figure 1A ). Given this result, 200 lM of MPP þ was selected for our further experiments. To assess the effect of MPP þ on autophagy and lysosomal biogenesis, the protein levels of LC3, SQSTM1/p62, and Lamp-1 were measured. As shown in Figure 1B , the autophagosome marker LC3-II and the lysosomal marker Lamp-1 was reduced in a time-dependent manner after MPP þ treatment, whereas p62, a substrate in the autophagic process, was increased. To further confirm the inhibition of autophagy by MPP Following auophagosome-lysosome fusion, the autolysosomes present as red puncta because GFP is more rapidly quenched by low lysosomal pH. Compared with the control group, MPP þ remarkably reduced the autophagosome formation as indicated by the disappeared red dots and the massive diffused yellow fluorescence ( Figure 1C ). Meanwhile, the pH-sensitive lysosome probe Lysotracker was examined to further demonstrate the state of lysosomal biogenesis after MPP þ treatment. As shown in Figure 1D , MPP þ induced a striking reduction in lysosome staining. Notably, the mRNA levels of LC3 and Lamp-1 were declined after treated with 200 lM MPP þ for 6 h ( Figure 1E ). To test whether the dysfunction of ALP was mediated by TFEB, the master regulator of autophagy and lysosomal biogenesis, the nuclear and cytoplasmic fractions were separated by subcellular fractionation for analyzing the distribution of TFEB upon MPP þ treatment. We found that MPP þ reduced the portion of TFEB in nuclear compartment whereas increased its portion in cytosol ( Figure 1F ). These results suggested that MPP þ impairs ALP function via inhibiting TFEB nuclear translocation.
STI-571 Alleviates MPP
1 -Induced Impairment of AutophagyLysosomal Pathway through Regulating TFEB Translocation Recent studies have illustrated that c-Abl could phosphorylate parkin, a-synuclein and p38 to mediate PD pathogenesis (Hebron et al., 2013; Imam et al., 2011; Wu et al., 2016) . The increased p62 was also observed transfecting WT c-Abl whereas kinase-dead (KD) c-Abl has no effect in SN4741 cells after MPP þ treatment ( Figure 2D ).
In order to further verify the effect of STI-571 on autophagy and lysosomal biogenesis, autophagosome formation (LC3 puncta) and Lysotracker were examined using confocal microscopy. As shown in Figures The above data demonstrated that c-Abl mediated MPP þ -induced dysfunction of ALP by inhibiting TFEB nuclear translocation. However, the molecular mechanisms by which c-Abl mediating MPP þ -triggered alteration of TFEB distribution remain unknown. Recent studies identified TFEB as a substrate of GSK3b.To determine whether GSK3b was involved in c-Abl mediated TFEB translocation, phosphorylation of GSK3b were monitored using antibody p-GSK3b-S9 and p-GSK3b-Y216 in MPP þ -treated SN4741 cells. The results shown that phosphorylation of GSK3b-S9 was reduced whereas phosphorylation of GSK3b-Y216 was enhanced by MPP þ , suggesting that MPP þ induced rescent mRFP-GFP-LC3B plasmid, and then treated as described in (B), followed by confocal microscopy study for LC3 dots formation. F, Staining with Lysosome tracker in SN4741 cells treated as described in (B). G, SN4741 cells treated as described in (B), the nuclear and cytosolic fractions were immunoblotted with antibodies indicated. H, Subcellular localization of the endogenous TFEB was detected by confocal microscopy, using an antibody against TFEB and Nuclei were stained with 4 0 , 6 0 -diamidino-2-phenylindole(DAPI). Scale bars represent 5 lm in all images. Experiments were independently repeated at least 3 times.
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activation of GSK3b ( Figure 3A ). In addition, the phosphorylation of GSK3b-Y216 induced by MPP þ is attenuated by STI-571 in SN4741 cells and in primary midbrain neurons (Figs. 3B and 3C). Meanwhile, GSK3b-Y216 phosphorylation was observed using WT c-Abl whereas KD c-Abl had no effect under MPP þ treatment ( Figure 3D ). Moreover, we examined whether pharmacological activation of c-Abl could induce GSK3b-Y216 phosphorylation. Treatment of SN4741 cells with DPH, a c-Abl activator, resulted in a significant phosphorylation of GSK3b-Y216 ( Figure 3E ). These data suggested that activated c-Abl phosphorylates GSK-3b-Y216, GSK-3b may serve as a substrate of c-Abl in MPP þ -mediated PD model. As c-Abl is a tyrosine kinase and the MPP þ -induced phosphorylation of GSK3b-Y216 is significantly reduced by STI-571, we next tested the possibility that GSK3b is a direct substrate of c-Abl. Hence, we performed co-immunoprecipitation experiments to define the interaction between c-Abl and GSK3b, and whether the interaction is influenced by MPP þ treatment. As shown in Figures 3F and 3G , c-Abl was co-precipitated with GSK3b and GSK3b was found in the proteins co-precipitated with c-Abl. Moreover, as we expected, the interaction between GSK3b and c-Abl was enhanced in MPP þ -treated SN4741 cells.
Taken together, these data suggested that c-Abl interacts with GSK3b and phosphorylates GSK3b at Y216, c-Abl inhibition alleviates MPP þ -induced phosphorylation of GSK3b-Y216.
The Phosphorylation of GSK3b-Tyr216 Induced by MPP 1 Was Not due to GSK3b Autophosphorylation Previous report suggested that GSK3b was a transitional intramolecular tyrosine kinase in formative stage. GSK3b itself autophosphorylates the Y216 by a HSP90-dependent manner in mammalian systems (Lochhead et al., 2006) . But whether GSK3b tyrosine autophosphorylation involved in phosphorylation of GSK3b-Y216 is unknown in PD. As shown in Figure 4 , the protein level of GSK3b and HSP90 do not change in SN4741 cells exposed to MPP þ , and MPP þ has no effect on the interaction of GSK3b and HSP90. Taken together, these results indicate that the phosphorylation of GSK3b-Y216 induced by MPP þ was not due to GSK3b autophosphorylation.
GSK3b Inhibition Alleviates MPP
1 -Induced Inhibition of Autophagy and Lysosomal Biogenesis Through Regulating TFEB Translocation Recent studies have illustrated that GSK3b is implicated in the pathogenesis of PD (Golpich et al., 2015) , in which autophagylysosomal system is usually dysregulated. To test whether GSK3b inhibition can alleviate PD through rescuing the function of autophagy-lysosomal pathway, SN4741 cells were treated with or without GSK3b-specific inhibitor CHIR-99021. In absence of CHIR-99021, MPP þ treatment led to nuclear TFEB decline, whereas CHIR-99021 increased the concentration of TFEB in the nuclear fraction in MPP þ -treated SN4741 cells ( Figure 5A ). Meantime, immunocytochemistry experiment consistently indicated that GSK3b inhibition resulted in an efficient translocation of TFEB to nucleus ( Figure 5B ). In addition, coimmunoprecipitation results showed that MPP þ treatment greatly enhanced the interaction between GSK3b and TFEB, which could be blocked by GSK3b-specific inhibitor CHIR-99021.
( Figure 5C ). The 14-3-3 protein could bind to phosphorylated TFEB to sequester it in the cytoplasm, thus inhibiting the nuclear translocation of TFEB as well as the activation of its target genes. Stronger interaction between 14-3-3 and TFEB was observed in SN4741 cells treated with MPP þ , which was mitigated by CHIR-99021 ( Figure 5C ). It is implied that decreased TFEB phosphorylation following GSK3b inhibition dissociated TFEB from 14-3-3 protein. Accordingly, the GSK3b inhibitor CHIR-99021 rescued the protein levels of LC3-II and LAMP-1, and reduced the p62 accumulation induced by MPP þ ( Figure 5D ).
Similar results were obtained following transfection of siRNAGSK3b in SN4741 cells ( Figure 5E ). To ensure the recuperation of autophagy and lysosomal biogenesis, the autophagosome formation (LC3 puncta) and Lysotracker were examined again. As shown in Figures tal cell lysates were immunoblotted with the indicated antibodies. F, SN4741 cells were transfected with mRFP-GFP-LC3B plasmid, and then treated as described in (A), followed by confocal microscopy study for LC3B dots formation. G, Staining with Lysosome tracker in SN4741 cells treated as described in (A). Scale bars represent 5 lm in all images. Experiments were independently repeated at least 3 times. (Park et al., 2015; Ryan et al., 2015) . To determine whether the protective effect of CHIR-99021 and STI-571 on MPP þ -induced neurotoxicity was dependent on ALP, the cell viability was measured by CCK-8 assay. As shown in Figures 6A and 6B , both CHIR-99021 and STI-571 treatment inhibited the MPP þ -induced cell death, and Chir-99021 or STI-571 treatment alone has no substantial effect on cell viability. However, inhibiting ALP by chloroquine or TFEB knockdown abrogated the protective effect of Chir-99021 or STI-571 on MPP þ -induced cell death ( Figure 6C ). These results suggested that c-Abl/GSk-3b inhibition could protect neurons from MPP þ -induced cell death which is dependent on the enhanced function of ALP mediated by TFEB.
DISCUSSION
c-Abl is a member of Abl family of nonreceptor tyrosine kinase, which is implicated in a variety of biological processes including the regulation of cell growth and survival, integrin signaling, actin polymerization, and cell migration. Recent studies showed that increased c-Abl activity, as measured by c-Abl level and phosphorylated c-Abl (tyrosine 412 and tyrosine 245), was observed in the substantia nigra (SN) and striatum of postmortem PD brain (Hebron et al., 2013; Ko et al., 2010) , which are pathologically affected in PD. Charbel et al. demonstrated that c-Abl activation was associated with accumulation of a-synuclein, whereas the overexpression of c-Abl increased the accumulation of a-synuclein in PD animal models, and administration of tyrosine kinase inhibitor Nilotinib ameliorated autophagic clearance of a-synuclein via decreasing c-Abl activity (Hebron et al., 2013) . Arthi Kanthasamy et al. discovered that pharmacological inhibition of c-Abl by Dasatinib abrogated rotenoneinduced microglial activation response through attenuating impairment of ALP (Lawana et al., 2017) . Imatinib (STI571), the cAbl tyrosine kinase inhibitor, has been shown to prevent the phosphorylation of c-Abl substrates, such as parkin, p38 and drp1, and subsequent dopaminergic neuronal loss (Ko et al., 2010; Wu et al., 2016; Zhou et al., 2017) . However, the effect of STI-571 on c-Abl mediated ALP dysfunction in PD model and its molecular mechanisms remained unclear. The present study demonstrated that c-Abl tyrosine kinase was a crucial component in inhibiting autophagy and lysosomal biogenesis, which were considered as critical processes in the turnover of misfolded proteins in response to MPP The cell viability of SN4741 cells was then measured by CCK-8 assay. (means6SEM; n ¼ 3; *P < .05; **P < .01) (C) SN4741 cells were transfected with control or TFEB siRNA, followed by MPP þ or Chir-99021 or STI-571 treatment for 24 h. The cell ability of SN4741 cells was then measured by CCK-8 assay (means6SEM; n ¼ 3; *P < .05; **P < .01).
nuclear translocation. Using multiple biochemical and cellular approaches, we identified that c-Abl directly interacted with GSK3b and phosphorylated it at Tyr216 in SN4741 cells exposed to MPP þ . The inhibition of c-Abl activity by STI-571 resulted in a significant reduction of Tyr216 phosphorylation of GSK3b. Similar results were also observed when transfecting kinasedead form c-Abl (K290R) plasmid to SN4741 cells under MPP þ treatment. Furthermore, phosphorylated GSK3b-Y216 was involved in the dysfunction of autophagy and lysosomal biogenesis through regulating TFEB subcellular localization.
It has been found that in postmortem PD brain, phosphorylation of GSK3b-Tyr216 was increased in the brain regions associated with PD pathology (Wills et al., 2010) . Moreover, previous studies demonstrated that GSK3b activity significantly increased both in vitro and in vivo PD models (Duka et al., 2009; Wang et al., 2007) . GSK3b is activated by phosphorylation of the tyrosine 216 residue located in the kinase domain and inactivated by phosphorylation of the N-terminal serine 9 residue. Most of studies are focusing on the deactivation of GSK3b, the phosphorylation of Ser9, whereas the phosphorylation of Tyr216 is thought to be constitutively active through autophosphorylation (Lochhead et al., 2006) . However, previous reports showed that Pyk-2 and Fyn kinases can phosphorylate GSK3b at Tyr216 (Gao et al., 2015) . In this work, we showed that c-Abl phosphorylated GSK3b at Tyr216, which was not autophosphorylation under MPP þ exposure in SN4741 cells.
Multiple lines of evidence indicated that aberrant autophagy was evident in vitro and rodent models of PD, as well as in human patients with PD (Anglade et al., 1997; Dagda et al., 2013; Dauer and Przedborski, 2003; Dehay et al., 2010) . Here, we showed that MPP þ induces dynamic changes in ALP function, which were correlated with the activation of GSK3b. We examined the relationship between GSK-b phosphorylation and ALP function after MPP þ treatment, as well as the expression of lysosomal and autophagic markers through GSK3b inhibition or genetic knockdown. The results showed that CHIR99021, an inhibitor of GSK3b, as well as knockdown of GSK3b, alleviated the impaired autophagy and lysosomal biogenesis induced by MPP þ , increased the expression of LC3-II, Lamp-1, reduced the accumulation of p62. Similar results were obtained by transfecting GFP-RFP-LC3B and Lysosomal staining in SN4741 cells through confocal microscopy. TFEB plays a pivotal role in autophagy and lysosomal biogenesis. Under baseline conditions, TFEB is distributed in both the nucleus and cytoplasm although it is predominantly located in the cytoplasm. While in the PD cases, nuclear TFEB level was significantly reduced He et al., 2018) . Because GSK3b has been identified as a regulator of TFEB , we analyzed the involvement of GSK3b in the regulation of TFEB nuclear translocation under MPP þ treatment. CHIR99021 significantly rescued the cytoplasm-to-nucleus shuttling of endogenous TFEB in MPP þ -treated SN4741cells, which was determined by nucleus/ cytoplasm fractionation experiment. Similar results were found by immunocytochemistry staining with confocal microscopy. Under normal condition, 14-3-3 protein interact with phosphorylated TFEB, preventing TFEB nuclear translocation, which is even more evident in PD model. As expected, the GSK3b inhibitor CHIR99021 impeded the interaction between 14-3-3 protein and TFEB by interfering the phosphorylation of TFEB.
We showed that STI-571 inhibited c-Abl-mediated GSK3b-Y216 phosphorylation and enhanced GSK3b-mediated TFEB nuclear translocation, therefore promoted ALP function. Nevertheless, further investigations are required to confirm whether the protective effect of STI-571 on ALP is due to the direct regulation of TFEB function by c-Abl. Moreover, the presence of blood-brain barrier possibly limits the function of most c-Abl inhibitors including STI-571 to reach the brain because of their low brain penetration. Hence, the development of high brain-permeable inhibitor of c-Abl and GSK3b would facilitate the therapeutic treatment for PD.
Recent studies show that c-Abl activation plays a pivotal role in a-synuclein-induced neurodegeneration; c-Abl impairs parkin's ubiquitin E3 ligase activity via phosphorylation, whereas the ubiquitin E3 ligase activity of parkin has a crucial neuroprotective function in mitochondria quality control through PINK1/ parkin signaling. So, a number of c-Abl inhibitors have been evaluated as potential disease modifier in PD. However, there are still many challenges for applying existing c-Abl inhibitors for PD therapy such as poor blood-brain barrier penetrance and off-target inhibition of other kinases. It is important to explore the novel c-Abl substrates which are involved in the pathogenesis of PD. It will open-up avenues for new therapeutic targets. The present study shows that GSK3b is a novel direct target of c-Abl (Figure 7) , offers a promising prospect of novel therapeutic target against PD.
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Supplementary data are available at Toxicological Sciences online. which enhances its kinase activity and promotes GSK3b-mediated TFEB phosphorylation. ALP dysfunction mediated by TFEB phosphorylation is involved in the neuronal cell death after MPP þ treatment.
